Diabetic nephropathy: diagnosis and treatment (Q38150065)

29 August 2017

Diabetic nephropathy: diagnosis and treatment (English)

1 reference

29 August 2017

1 reference

Daniel Fineberg

1

1 reference

PubMed ID

24100266

29 August 2017

Karin A M Jandeleit-Dahm

series ordinal

2

1 reference

PubMed ID

24100266

29 August 2017

Mark E Cooper

series ordinal

3

1 reference

29 August 2017

8 October 2013

1 reference

Nature Reviews Endocrinology

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

12

1 reference

29 August 2017

713-723

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.184

29 August 2017

0 references

cites work

Nephropathy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Epidemiology of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Standards of medical care in diabetes--2012

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Serum concentration of cystatin C and risk of end-stage renal disease in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Is diabetic nephropathy disappearing from clinical practice?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Diabetic kidney disease with and without albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Normoalbuminuric diabetic kidney disease in the U.S. population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Investigation of ACE, ACE2 and AGTR1 genes for association with nephropathy in Type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Dia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

GWAS of diabetic nephropathy: is the GENIE out of the bottle?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

New susceptibility loci associated with kidney disease in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Diabetes complications: the microRNA perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Correction: Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Mechanisms of diabetic complications.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Pathologic classification of diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of a multifactorial intervention on mortality in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Meta-analysis confirms raised risk of bladder cancer from pioglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

SGLT2 inhibition--a novel strategy for diabetes treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Cardiovascular events during differing hypertension therapies in patients with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Avosentan for overt diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Statin use in patients with diabetes and kidney disease: the Japanese experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of fibrates in kidney disease: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Emerging drugs for managing kidney disease in patients with diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Interactions between renin angiotensin system and advanced glycation in the kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Into the light? Diabetic nephropathy and vitamin D.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Biochemistry and molecular cell biology of diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The effect of ruboxistaurin on nephropathy in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Pirfenidone for diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Diabetes: bardoxolone improves kidney function in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Nrf2-Keap1 defines a physiologically important stress response mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

The extinguished BEACON of bardoxolone: not a Monday morning quarterback story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Renal and retinal effects of enalapril and losartan in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

Lowering blood pressure reduces renal events in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.184

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

31 March 2020

1 reference

12 December 2020

Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

1 reference

12 December 2020

Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.

1 reference

12 December 2020

One year course of oral sulodexide in the management of diabetic nephropathy.

1 reference

12 December 2020

Urinary microRNA profiling in the nephropathy of type 1 diabetes

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2013.184

1 reference

29 August 2017

1 reference

PubMed ID

24100266